CSIMarket
 


Prothena Corporation Public Limited Company  (PRTA)
Other Ticker:  
 

Cumulative Prothena Public Limited's Quick Ratio for Trailing Twelve Months Period

PRTA's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

PRTA Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 13.45 % 5.48 % 78.44 % 33.94 % 49.91 %
Y / Y Cash & cash equivalent Growth -12.89 % 35.36 % 29.54 % 26.37 % 22.68 %
Quick Ratio for Trailing Twelve Months Period 11.42 12.17 11.53 12.65 12.73
Total Ranking # 75 # 159 # 199 # 194 # 212
Seq. Current Liabilities Growth 6.6 % -25.42 % 46.4 % -2.52 % -0.89 %
Seq. Cash & cash equivalent Growth -7.76 % 1.79 % -3.95 % -3.41 % 43.33 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the IV. Quarter to $57 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 11.42 below Prothena Corporation Public Limited Company average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Prothena Public Limited. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about PRTA
Quick Ratio PRTA in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 30
Sector # 48
S&P 500 # 80


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
28.48 15.95 10.92
(June 30. 2015)   (Jun 30 2021)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Inhibitor Therapeutics Inc   30.02 
Morphic Holding inc   29.63 
Ars Pharmaceuticals Inc   29.51 
Design Therapeutics Inc   29.08 
Cohbar Inc   27.36 
Cyteir Therapeutics Inc   27.13 
Terns Pharmaceuticals Inc   25.94 
Atossa Therapeutics Inc   25.85 
Theseus Pharmaceuticals Inc   25.84 
Eliem Therapeutics Inc   25.00 
Astria Therapeutics inc   24.41 
Briacell Therapeutics Corp   24.30 
Bright Minds Biosciences Inc   24.16 
Belite Bio Inc  23.58 
Xenon Pharmaceuticals Inc   23.53 
Eqrx Inc   23.06 
Acelyrin Inc   22.77 
Aprea Therapeutics Inc   22.56 
Lixte Biotechnology Holdings Inc   21.56 
Sio Gene Therapies Inc   21.43 
Janux Therapeutics Inc   21.10 
Pmv Pharmaceuticals Inc   20.92 
Savara Inc   20.70 
Edgewise Therapeutics inc   20.64 
Nuvalent Inc   20.36 
Kura Oncology Inc   20.11 
Akero Therapeutics Inc   19.46 
Lantern Pharma Inc   19.27 
Pliant Therapeutics Inc   19.23 
Medicinova Inc   18.98 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com